Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380098 | 0.82 | MME (0.58) | MMETGFBR1ACEALDH1A1THRB | |
| SCHEMBL9650023 | 0.82 | MME (0.58) | MMETGFBR1ACEALDH1A1THRB | |
| SCHEMBL12017867 | 0.82 | ALDH1A1 (0.47) | MMETGFBR1ALDH1A1THRB | |
| SCHEMBL14520476 | 0.82 | MME (0.41) | MMETGFBR1ACEALDH1A1THRB | |
| SCHEMBL14163011 | 0.82 | MME (0.58) | MMETGFBR1ACEALDH1A1THRB | |
| SCHEMBL12537161 | 0.82 | ALDH1A1 (0.47) | MMETGFBR1ALDH1A1THRB | |
| SCHEMBL17324228 | 0.80 | ACE (0.52) | MMEACETHRB | |
| SCHEMBL13380099 | 0.80 | MMP3 (0.42) | MMETGFBR1ACEMMP8 | |
| SCHEMBL25542666 | 0.80 | ACE (0.34) | ACECYP2C9CYP2C19CNR2 | |
| SCHEMBL20021565 | 0.80 | ALDH1A1 (0.45) | MMEALDH1A1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | GPR6, GALR3, NTSR1 | MME 1295/4885TGFBR1 1256/4885ACE 3740/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | MME 130/4885TGFBR1 1533/4885ACE 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.